300434 金石亚药
已收盘 07-25 15:00:00
资讯
新帖
简况
金石亚药:7月24日高管林强减持股份合计2万股
证券之星 · 07-25 13:02
金石亚药:7月24日高管林强减持股份合计2万股
金石亚药:7月21日至7月22日高管林强减持股份合计96.62万股
证券之星 · 07-23
金石亚药:7月21日至7月22日高管林强减持股份合计96.62万股
金石亚药:7月15日高管林强减持股份合计10万股
证券之星 · 07-16
金石亚药:7月15日高管林强减持股份合计10万股
金石亚药最新公告:签订地奈德软膏产品推广委托协议
证券之星 · 07-04
金石亚药最新公告:签订地奈德软膏产品推广委托协议
金石亚药(300434.SZ)子公司亚洲制药拟向亚克药业增资2亿元
智通财经 · 07-04
金石亚药(300434.SZ)子公司亚洲制药拟向亚克药业增资2亿元
金石亚药(300434.SZ)董事林强拟减持不超0.39%股份
智通财经 · 06-19
金石亚药(300434.SZ)董事林强拟减持不超0.39%股份
每周股票复盘:金石亚药(300434)2024年年度权益分派实施
证券之星 · 06-13
每周股票复盘:金石亚药(300434)2024年年度权益分派实施
金石亚药:目前公司持有杭州领业医药32.4304%的股权
证券之星 · 05-29
金石亚药:目前公司持有杭州领业医药32.4304%的股权
金石亚药:公司RTP带式缠绕管设备主要用于石油天然气等工业领域的中高压柔性管道的制造
证券之星 · 05-22
金石亚药:公司RTP带式缠绕管设备主要用于石油天然气等工业领域的中高压柔性管道的制造
金石亚药:公司股东高雅萍女士持股均已严格按照相关规定进行了披露
证券之星 · 05-14
金石亚药:公司股东高雅萍女士持股均已严格按照相关规定进行了披露
金石亚药:公司积极通过完善公司治理结构等措施保障中小股东利益
证券之星 · 05-14
金石亚药:公司积极通过完善公司治理结构等措施保障中小股东利益
金石亚药:公司一直高度重视市值管理
证券之星 · 05-14
金石亚药:公司一直高度重视市值管理
金石亚药(300434)2025年一季报简析:净利润减30.02%
证券之星 · 04-25
金石亚药(300434)2025年一季报简析:净利润减30.02%
金石亚药:公司一直高度重视市值管理通过多项举措推动公司市值和内在价值的可持续增长
证券之星 · 04-25
金石亚药:公司一直高度重视市值管理通过多项举措推动公司市值和内在价值的可持续增长
金石亚药:上市公司股价受多种因素的综合影响
证券之星 · 04-25
金石亚药:上市公司股价受多种因素的综合影响
图解金石亚药一季报:第一季度单季净利润同比减30.02%
证券之星 · 04-24
图解金石亚药一季报:第一季度单季净利润同比减30.02%
金石亚药(300434.SZ)发布一季度业绩,归母净利润6285.13万元,下降30.02%
智通财经 · 04-24
金石亚药(300434.SZ)发布一季度业绩,归母净利润6285.13万元,下降30.02%
金石亚药:公司正在进行PBO材料表面金属化处理的真空镀膜设备的研发工作
证券之星 · 02-26
金石亚药:公司正在进行PBO材料表面金属化处理的真空镀膜设备的研发工作
金石亚药最新公告:证券事务代表何欣因个人原因辞职
证券之星 · 02-20
金石亚药最新公告:证券事务代表何欣因个人原因辞职
金石亚药:关于证券事务代表辞职的公告
新浪财经-鹰眼工作室 · 02-20
金石亚药:关于证券事务代表辞职的公告
加载更多
公司概况
公司名称:
四川金石亚洲医药股份有限公司
所属行业:
医药制造业
上市日期:
2015-04-24
主营业务:
四川金石亚洲医药股份有限公司的主营业务是药品(包括化学药、中药饮片等)和保健食品(包括稀有人参皂苷产品和维生素矿物质补益类产品)的研发、生产与销售;增强塑料复合管道技术的研发和应用、真空镀膜设备的研发和制造。公司的主要产品是快克、小快克、保健品、贴牌及批发零售药品、其他医药产品、成套生产线、机械配件及其他、房产租赁、管理及其他。
发行价格:
10.57
{"stockData":{"symbol":"300434","market":"SZ","secType":"STK","nameCN":"金石亚药","latestPrice":10.41,"timestamp":1753427010000,"preClose":10.55,"halted":0,"volume":20440420,"delay":0,"changeRate":-0.0133,"floatShares":342000000,"shares":401999999,"eps":0.1613,"marketStatus":"已收盘","change":-0.14,"latestTime":"07-25 15:00:00","open":10.55,"high":10.71,"low":10.36,"amount":215000000,"amplitude":0.0332,"askPrice":10.42,"askSize":103,"bidPrice":10.41,"bidSize":317,"shortable":0,"etf":0,"ttmEps":0.1613,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753666200000},"marketStatusCode":5,"adr":0,"adjPreClose":10.55,"symbolType":"stock","openAndCloseTimeList":[[1753407000000,1753414200000],[1753419600000,1753426800000]],"highLimit":11.61,"lowLimit":9.5,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":401743872,"isCdr":false,"pbRate":1.69,"roa":"--","peRate":64.538128,"roe":"2.53%","epsLYR":0.23,"committee":0.097543,"marketValue":4182000000,"turnoverRate":0.0597,"status":1,"floatMarketCap":3561000000},"requestUrl":"/m/hq/s/300434","defaultTab":"news","newsList":[{"id":"2554760903","title":"金石亚药:7月24日高管林强减持股份合计2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2554760903","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554760903?lang=zh_cn&edition=full","pubTime":"2025-07-25 21:02","pubTimestamp":1753448550,"startTime":"0","endTime":"0","summary":"证券之星消息,根据7月25日市场公开信息、上市公司公告及交易所披露数据整理,金石亚药(300434)最新董监高及相关人员股份变动情况:2025年7月24日公司董秘,董事,高管林强共减持公司股份2.0万股,占公司总股本为0.005%。变动期间公司股价上涨1.74%,7月24日当日收盘报10.55元。金石亚药近半年内的董监高及核心技术人员增减持详情如下:金石亚药的高管列表及最新持股情况如下:该股最近90天内无机构评级。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072500037256.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300434","BK0077"],"gpt_icon":0},{"id":"2553572243","title":"金石亚药:7月21日至7月22日高管林强减持股份合计96.62万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2553572243","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553572243?lang=zh_cn&edition=full","pubTime":"2025-07-23 21:02","pubTimestamp":1753275758,"startTime":"0","endTime":"0","summary":"证券之星消息,根据7月23日市场公开信息、上市公司公告及交易所披露数据整理,金石亚药(300434)最新董监高及相关人员股份变动情况:2025年7月21日至2025年7月22日公司董秘,董事,高管林强共减持公司股份96.62万股,占公司总股本为0.2405%。变动期间公司股价下跌1.96%,7月22日当日收盘报10.49元。金石亚药近半年内的董监高及核心技术人员增减持详情如下:金石亚药的高管列表及最新持股情况如下:该股最近90天内无机构评级。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072300038486.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300434","BK0028","BK0077"],"gpt_icon":0},{"id":"2551123136","title":"金石亚药:7月15日高管林强减持股份合计10万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2551123136","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551123136?lang=zh_cn&edition=full","pubTime":"2025-07-16 21:02","pubTimestamp":1752670941,"startTime":"0","endTime":"0","summary":"证券之星消息,根据7月16日市场公开信息、上市公司公告及交易所披露数据整理,金石亚药(300434)最新董监高及相关人员股份变动情况:2025年7月15日公司董秘,董事,高管林强共减持公司股份10.0万股,占公司总股本为0.0249%。变动期间公司股价下跌1.08%,7月15日当日收盘报10.12元。金石亚药近半年内的董监高及核心技术人员增减持详情如下:金石亚药的高管列表及最新持股情况如下:该股最近90天内无机构评级。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071600036571.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","300434","BK0239","BK0028"],"gpt_icon":0},{"id":"2548369903","title":"金石亚药最新公告:签订地奈德软膏产品推广委托协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2548369903","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548369903?lang=zh_cn&edition=full","pubTime":"2025-07-04 16:58","pubTimestamp":1751619522,"startTime":"0","endTime":"0","summary":"金石亚药(300434.SZ)公告称,公司全资三级子公司浙江快克拟与公司参股公司杭州领业医药有限公司签订产品推广委托协议,推广药品为地奈德软膏,推广期限为自协议生效之日起至2026年12月31日,交易金额预计不高于1500万元(含税)。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070400026561.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300434","BK0077","BK0239"],"gpt_icon":0},{"id":"2548363636","title":"金石亚药(300434.SZ)子公司亚洲制药拟向亚克药业增资2亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548363636","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548363636?lang=zh_cn&edition=full","pubTime":"2025-07-04 16:03","pubTimestamp":1751616234,"startTime":"0","endTime":"0","summary":"智通财经APP讯,金石亚药(300434.SZ)发布公告,根据公司发展战略和公司全资二级子公司浙江亚克药业有限公司(简称“亚克药业”)的业务发展需要,公司全资一级子公司海南亚洲制药股份有限公司(简称“亚洲制药”)拟以自有资金人民币2亿元向亚克药业增资。本次增资完成后,亚克药业的注册资本由人民币1.5亿元增加至3.5亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1314008.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","BK1574","BK0028","BK1191","BK0239","300434","01477"],"gpt_icon":0},{"id":"2544016480","title":"金石亚药(300434.SZ)董事林强拟减持不超0.39%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2544016480","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544016480?lang=zh_cn&edition=full","pubTime":"2025-06-19 20:45","pubTimestamp":1750337130,"startTime":"0","endTime":"0","summary":"智通财经APP讯,金石亚药(300434.SZ)公告,公司董事、副总裁、董事会秘书林强先生计划在减持计划公告之日起十五个交易日后的三个月内以集中竞价交易或大宗交易方式,减持所持有的公司股份不超过156.62万股(占公司总股本比例0.39%)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1307444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0077","BK0028","300434"],"gpt_icon":0},{"id":"2543563224","title":"每周股票复盘:金石亚药(300434)2024年年度权益分派实施","url":"https://stock-news.laohu8.com/highlight/detail?id=2543563224","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543563224?lang=zh_cn&edition=full","pubTime":"2025-06-14 03:37","pubTimestamp":1749843431,"startTime":"0","endTime":"0","summary":"截至2025年6月13日收盘,金石亚药报收于9.9元,较上周的9.91元下跌0.1%。本周,金石亚药6月10日盘中最高价报10.98元。本周关注点公司公告汇总:金石亚药2024年年度权益分派方案已获股东大会审议通过公司公告汇总金石亚药2024年年度权益分派方案已获2025年5月23日召开的2024年年度股东大会审议通过。本次分派对象为截止2025年6月18日下午深圳证券交易所收市后在中国结算深圳分公司登记在册的本公司全体股东。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061400008067.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300434","BK0077","BK0028","BK0239"],"gpt_icon":0},{"id":"2539828388","title":"金石亚药:目前公司持有杭州领业医药32.4304%的股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2539828388","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539828388?lang=zh_cn&edition=full","pubTime":"2025-05-29 08:36","pubTimestamp":1748478980,"startTime":"0","endTime":"0","summary":"证券之星消息,金石亚药05月28日在投资者关系平台上答复投资者关心的问题。目前,公司持有杭州领业医药32.4304%的股权。杭州领业医药以核心技术为驱动,解决临床未满足需求为目标,深耕皮肤科学领域,开发创新药、仿制药和皮肤健康产品,做皮肤健康的守护者。该公司相关情况请以领业医药官方渠道发布的信息为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052900005000.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK1161","BK0077","BK0239","BK1515","159938","300434","BK1574","09939"],"gpt_icon":0},{"id":"2537965776","title":"金石亚药:公司RTP带式缠绕管设备主要用于石油天然气等工业领域的中高压柔性管道的制造","url":"https://stock-news.laohu8.com/highlight/detail?id=2537965776","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537965776?lang=zh_cn&edition=full","pubTime":"2025-05-22 09:15","pubTimestamp":1747876550,"startTime":"0","endTime":"0","summary":"证券之星消息,金石亚药05月21日在投资者关系平台上答复投资者关心的问题。公司2025年第一季度报告已于2025年4月25日在指定信息披露媒体发布,敬请关注。公司RTP带式缠绕管设备主要用于石油天然气等工业领域的中高压柔性管道的制造。2024年,产品成功出口至沙特、伊朗、印度、印度尼西亚等国家,该技术目前处于国际国内领先水平,市场前景广阔。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052200005790.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["QGmain","BK0028","UGAZ","DGAZ","BK0239","NGmain","BK0077","MNGmain","300434","UNG"],"gpt_icon":0},{"id":"2535401608","title":"金石亚药:公司股东高雅萍女士持股均已严格按照相关规定进行了披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2535401608","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535401608?lang=zh_cn&edition=full","pubTime":"2025-05-14 16:36","pubTimestamp":1747211769,"startTime":"0","endTime":"0","summary":"证券之星消息,金石亚药(300434)05月14日在投资者关系平台上答复投资者关心的问题。投资者提问:高雅萍持股过高是否影响公司未来发展?但已影响了股价下跌,她是否合法合规买入的?金石亚药回复:尊敬的投资者,您好!公司股东高雅萍女士持股均已严格按照《证券法》、《上市公司收购管理办法》 、《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自律监管指引第10号——股份变动管理》等相关法律法规的规定进行了披露。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025051400026208.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0077","300434"],"gpt_icon":0},{"id":"2535092253","title":"金石亚药:公司积极通过完善公司治理结构等措施保障中小股东利益","url":"https://stock-news.laohu8.com/highlight/detail?id=2535092253","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535092253?lang=zh_cn&edition=full","pubTime":"2025-05-14 15:21","pubTimestamp":1747207284,"startTime":"0","endTime":"0","summary":"证券之星消息,金石亚药(300434)05月14日在投资者关系平台上答复投资者关心的问题。投资者提问:公司如何保障广大小股东利益的,具体内容方式?是否应该在公开招聘市场寻找更合适的业务管理人员呢?金石亚药回复:尊敬的投资者,您好!公司积极通过完善公司治理结构,落实现金分红,提升信息披露质量,增加信息透明度,多渠道与投资者保持沟通等多项措施切实保障广大中小股东利益。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025051400019368.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0077","300434"],"gpt_icon":0},{"id":"2535092269","title":"金石亚药:公司一直高度重视市值管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2535092269","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535092269?lang=zh_cn&edition=full","pubTime":"2025-05-14 15:21","pubTimestamp":1747207270,"startTime":"0","endTime":"0","summary":"证券之星消息,金石亚药05月14日在投资者关系平台上答复投资者关心的问题。贵公司生产都正常开展吗?公司一直高度重视市值管理,通过持续聚焦核心业务,不断完善公司治理结构,优化公司产业布局,提升信息披露质量,加强投资者沟通等多项举措,积极推动公司市值和内在价值的可持续增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025051400019354.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300434","BK0239","BK0077"],"gpt_icon":0},{"id":"2530191826","title":"金石亚药(300434)2025年一季报简析:净利润减30.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530191826","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530191826?lang=zh_cn&edition=full","pubTime":"2025-04-26 06:39","pubTimestamp":1745620742,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期金石亚药发布2025年一季报。根据财报显示,金石亚药净利润减30.02%。截至本报告期末,公司营业总收入2.91亿元,同比下降19.65%,归母净利润6285.13万元,同比下降30.02%。去年的净利率为8.03%,算上全部成本后,公司产品或服务的附加值一般。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042600007391.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300434"],"gpt_icon":0},{"id":"2530653972","title":"金石亚药:公司一直高度重视市值管理通过多项举措推动公司市值和内在价值的可持续增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2530653972","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530653972?lang=zh_cn&edition=full","pubTime":"2025-04-25 16:30","pubTimestamp":1745569845,"startTime":"0","endTime":"0","summary":"证券之星消息,金石亚药(300434)04月25日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好!证监会:上市公司要主动担负起稳市值、稳市场、稳信心的责任,将市值管理作为一项长期战略管理行为。请问:公司有何措施?金石亚药回复:尊敬的投资者,您好!公司一直高度重视市值管理,通过持续聚焦核心业务,不断完善公司治理结构,优化公司产业布局,提升信息披露质量,加强投资者沟通等多项举措,积极推动公司市值和内在价值的可持续增长。感谢您的关注!以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042500025281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300434","BK0239","BK0077"],"gpt_icon":0},{"id":"2530972600","title":"金石亚药:上市公司股价受多种因素的综合影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2530972600","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530972600?lang=zh_cn&edition=full","pubTime":"2025-04-25 16:30","pubTimestamp":1745569838,"startTime":"0","endTime":"0","summary":"证券之星消息,金石亚药04月25日在投资者关系平台上答复投资者关心的问题。上市公司股价受多种因素的综合影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042500025268.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300434","BK0239","BK0077"],"gpt_icon":0},{"id":"2530966351","title":"图解金石亚药一季报:第一季度单季净利润同比减30.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530966351","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530966351?lang=zh_cn&edition=full","pubTime":"2025-04-25 02:05","pubTimestamp":1745517912,"startTime":"0","endTime":"0","summary":"证券之星消息,金石亚药2025年一季报显示,公司主营收入2.91亿元,同比下降19.65%;归母净利润6285.13万元,同比下降30.02%;扣非净利润5773.03万元,同比下降34.13%;负债率15.08%,投资收益-333.02万元,财务费用-58.68万元,毛利率60.27%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042500001268.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300434"],"gpt_icon":0},{"id":"2529138602","title":"金石亚药(300434.SZ)发布一季度业绩,归母净利润6285.13万元,下降30.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529138602","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529138602?lang=zh_cn&edition=full","pubTime":"2025-04-24 18:59","pubTimestamp":1745492350,"startTime":"0","endTime":"0","summary":"智通财经APP讯,金石亚药(300434.SZ)发布2025年第一季度报告,该公司营业收入为2.91亿元,同比减少19.65%。归属于上市公司股东的净利润为6285.13万元,同比减少30.02%。归属于上市公司股东的扣除非经常性损益的净利润为5773.03万元,同比减少34.13%。基本每股收益为0.1564元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1284151.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300434"],"gpt_icon":0},{"id":"2514886212","title":"金石亚药:公司正在进行PBO材料表面金属化处理的真空镀膜设备的研发工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2514886212","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514886212?lang=zh_cn&edition=full","pubTime":"2025-02-26 17:00","pubTimestamp":1740560432,"startTime":"0","endTime":"0","summary":"证券之星消息,金石亚药02月26日在投资者关系平台上答复投资者关心的问题。是否能用在机器人?公司不涉及生产PBO材料,目前正在进行PBO材料表面金属化处理的真空镀膜设备的研发工作。是不是同一投资者?公司与金石基金并无关联关系。公司证券简称“金石亚药”是公司全称的缩写,同时也代表着公司对产品、服务及技术如金石般孜孜不倦不断求索的精神内核。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022600029422.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","BK0028","300434"],"gpt_icon":0},{"id":"2512941654","title":"金石亚药最新公告:证券事务代表何欣因个人原因辞职","url":"https://stock-news.laohu8.com/highlight/detail?id=2512941654","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512941654?lang=zh_cn&edition=full","pubTime":"2025-02-20 16:51","pubTimestamp":1740041517,"startTime":"0","endTime":"0","summary":"金石亚药公告称,公司董事会于2025年2月19日收到证券事务代表何欣的书面辞呈。何欣因个人原因申请辞去公司证券事务代表职务,且辞职后不再担任公司任何职务。以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022000027174.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300434","161027","BK0077","BK0239","BK0028"],"gpt_icon":0},{"id":"2512413502","title":"金石亚药:关于证券事务代表辞职的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2512413502","media":"新浪财经-鹰眼工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512413502?lang=zh_cn&edition=full","pubTime":"2025-02-20 16:20","pubTimestamp":1740039600,"startTime":"0","endTime":"0","summary":"四川金石亚洲医药股份有限公司关于证券事务代表辞职的公告本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、误导性陈述或重大遗漏。四川金石亚洲医药股份有限公司董事会于2025年2月19日收到公司两名证券事务代表之一何欣女士提交的书面辞呈。何欣女士因个人原因申请辞去公司证券事务代表职务,且辞职后不再担任公司任何职务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2025-02-20/doc-inemcpfh2348682.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300434","BK0077","BK0239","161027","BK0028"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1753546546971,"stockEarnings":[{"period":"1week","weight":-0.0271},{"period":"1month","weight":0.1122},{"period":"3month","weight":0.3635},{"period":"6month","weight":0.2527},{"period":"1year","weight":0.481},{"period":"ytd","weight":0.2709}],"compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.0398},{"period":"3month","weight":0.0906},{"period":"6month","weight":0.1048},{"period":"1year","weight":0.2449},{"period":"ytd","weight":0.0722}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"四川金石亚洲医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"19993人(较上一季度增加9.01%)","perCapita":"17112股","listingDate":"2015-04-24","address":"四川省成都市双流区九江镇万家社区","registeredCapital":"40174万元","survey":" 四川金石亚洲医药股份有限公司的主营业务是药品(包括化学药、中药饮片等)和保健食品(包括稀有人参皂苷产品和维生素矿物质补益类产品)的研发、生产与销售;增强塑料复合管道技术的研发和应用、真空镀膜设备的研发和制造。公司的主要产品是快克、小快克、保健品、贴牌及批发零售药品、其他医药产品、成套生产线、机械配件及其他、房产租赁、管理及其他。","listedPrice":10.57},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"金石亚药(300434)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供金石亚药(300434)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"金石亚药,300434,金石亚药股票,金石亚药股票老虎,金石亚药股票老虎国际,金石亚药行情,金石亚药股票行情,金石亚药股价,金石亚药股市,金石亚药股票价格,金石亚药股票交易,金石亚药股票购买,金石亚药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"金石亚药(300434)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供金石亚药(300434)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}